These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 27035535)

  • 41. Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.
    Gerhard DM; Wohleb ES; Duman RS
    Drug Discov Today; 2016 Mar; 21(3):454-64. PubMed ID: 26854424
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Is there anything really novel on the antidepressant horizon?
    Murrough JW; Charney DS
    Curr Psychiatry Rep; 2012 Dec; 14(6):643-9. PubMed ID: 22996298
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects.
    Lepow L; Luckenbaugh DA; Park L; Henter ID; Zarate CA
    J Psychiatr Res; 2017 Mar; 86():55-57. PubMed ID: 27914292
    [No Abstract]   [Full Text] [Related]  

  • 44. Targeting glutamate signalling in depression: progress and prospects.
    Murrough JW; Abdallah CG; Mathew SJ
    Nat Rev Drug Discov; 2017 Jul; 16(7):472-486. PubMed ID: 28303025
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mechanism of action of ketamine.
    Stahl SM
    CNS Spectr; 2013 Aug; 18(4):171-4. PubMed ID: 23866089
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ketamine: relief from chronic pain through actions at the NMDA receptor?
    Meller ST
    Pain; 1996 Dec; 68(2-3):435-6. PubMed ID: 9121834
    [No Abstract]   [Full Text] [Related]  

  • 47. Rapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression.
    Drewniany E; Han J; Hancock C; Jones RL; Lim J; Nemat Gorgani N; Sperry JK; Yu HJ; Raffa RB
    J Clin Pharm Ther; 2015 Apr; 40(2):125-30. PubMed ID: 25545040
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reply to S.T. Meller: Ketamine: relief from chronic pain through actions at the NMDA receptor.
    Eide PK; Stubhaug A; Breivik H; Oye I
    Pain; 1997 Aug; 72(1-2):289-91. PubMed ID: 9272819
    [No Abstract]   [Full Text] [Related]  

  • 49. The NMDA receptor as a therapeutic target in major depressive disorder.
    Pittenger C; Sanacora G; Krystal JH
    CNS Neurol Disord Drug Targets; 2007 Apr; 6(2):101-15. PubMed ID: 17430148
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression.
    Sos P; Klirova M; Novak T; Kohutova B; Horacek J; Palenicek T
    Neuro Endocrinol Lett; 2013; 34(4):287-93. PubMed ID: 23803871
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The role of mTOR in depression and antidepressant responses.
    Abelaira HM; Réus GZ; Neotti MV; Quevedo J
    Life Sci; 2014 Apr; 101(1-2):10-4. PubMed ID: 24582593
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Ketamine--a new treatment option for therapy-resistant depression].
    Köhler S; Betzler F
    Fortschr Neurol Psychiatr; 2015 Feb; 83(2):91-7. PubMed ID: 25723773
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition.
    Miller OH; Moran JT; Hall BJ
    Neuropharmacology; 2016 Jan; 100():17-26. PubMed ID: 26211972
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Ketamine from an anticonvulsant perspective].
    Mion G; Rüttimann M
    Ann Fr Anesth Reanim; 1997; 16(8):1045-6. PubMed ID: 9750654
    [No Abstract]   [Full Text] [Related]  

  • 55. Ketamine and other potential glutamate antidepressants.
    Dutta A; McKie S; Deakin JFW
    Psychiatry Res; 2015 Jan; 225(1-2):1-13. PubMed ID: 25467702
    [TBL] [Abstract][Full Text] [Related]  

  • 56. NMDA antagonists under investigation for the treatment of major depressive disorder.
    Pochwat B; Pałucha-Poniewiera A; Szewczyk B; Pilc A; Nowak G
    Expert Opin Investig Drugs; 2014 Sep; 23(9):1181-92. PubMed ID: 24818801
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The role of the glutamatergic system in pathophysiology and pharmacotherapy for depression: preclinical and clinical data].
    Paslakis G; Gass P; Deuschle M
    Fortschr Neurol Psychiatr; 2011 Apr; 79(4):204-12. PubMed ID: 21117011
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ketamine for restless legs syndrome.
    Friedman R
    Anesth Analg; 2003 Apr; 96(4):1238-1239. PubMed ID: 12651704
    [No Abstract]   [Full Text] [Related]  

  • 59. Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases.
    Paul R; Schaaff N; Padberg F; Möller HJ; Frodl T
    World J Biol Psychiatry; 2009; 10(3):241-4. PubMed ID: 19224412
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ketamine analgesia, NMDA receptors and the gates of perception.
    Oye I
    Acta Anaesthesiol Scand; 1998 Aug; 42(7):747-9. PubMed ID: 9698947
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.